Skip to main content

Branded Pharmaceuticals

Positive initiatives in therapeutic areas

At Consilient Health, innovative solutions for patient health are our focus.

We offer a wide range of prescription products including an established, market-leading portfolio of oral contraceptives pills, a range of licensed vitamin D products and a specialist urology product. We partner with the NHS to drive reliable provision of high-quality medicines and cost-savings for the NHS, complemented by comprehensive support programmes for both medical professionals and patients.

Therapeutic Areas

Contact us to learn more about our UK portfolio of products

Contact us

Women’s Health

Consilient Health’s market-leading portfolio of oral contraceptives has been designed to meet the differing needs of patients within the context of UK Medical Eligibility Criteria. This patient-centric approach enables us to provide a simplified yet innovative approach in the complex contraceptive market supported by educational resources for patients and healthcare professionals.

Women's Health

To learn more about our Women’s Health portfolio and to know your contraceptives please visit

knowyourcontraceptives.co.uk

Endocrinology Portfolio Information

Since launching our first endocrinology product in 2014, Consilient Health has successfully launched a further 9 products in this therapeutic area with future launches planned.

It is our ambition to provide a range of bone health products that meet prescriber’s and patient’s needs. Providing innovative solutions for prescribers and patients is a key element of our offering.

Having now established Consilient Health as a long term strategic partner, we look forward to continuing to grow our presence in this area over the coming years.

Endocrinology Portfolio

To learn more about our portfolio please visit

vitamin-d3.co.uk

Urology

Consilient Health is proud to have built on its rich heritage in women’s health and endocrinology with the recent UK launch of its first specialist urology product. Used to treat a rare and potentially debilitating urological condition, this launch is in keeping with our desire to bring to the market medicines that have a clear differentiation and where there is an unmet clinical need.

Urology

Contact us to find out more about our Urology portfolio

Contact us

Cardiovascular

Consilient Health is very pleased to include cardiovascular products within its portfolio. These contribute towards managing patients with long term conditions and can offer benefits to patients such as reduction of their pill burden, or titration of dosing using the same product. The cardiovascular products are attractive with the dosing range and combinations available.

Cardiovascular

Contact us to learn more about our Cardiovascular portfolio

Contact us

Partnering with our branded team in the UK

Consilient Health has developed strong relationships with partners both in the UK and Europe. Our branded pharmaceutical business began with the launch and successful commercialisation of a branded oral contraception range in 2010. This has since been followed by additional launches of InVita D3®, Calci-D®, Bentexo® and elmiron®.

Current areas of focus for Consilient Health are predominately within the fields of women’s health, bone health, urology and endocrinology and we are always looking to expand our portfolio with further innovative medicines.

 

We have an exceptionally knowledgeable team in the UK with a wealth of experience in bringing branded medicines to market. Our team understands the needs of the UK’s patients and with the help of our experienced representatives reaches all areas of the UK allowing us to maintain strong relationships with CCG’s and dispensing doctor while also providing support and education for patients and healthcare professionals.

We have a track record of being a resourceful, trusted partner of choice, demonstrating professionalism with integrity and delivering quality and value for all our partners.

With the expertise in the Consilient Health UK office, we offer our partners insight and understanding to optimise the commercial success of your medicines and ensure that patients gain access to the medicines they need. To discuss our capabilities as a partner for the UK please get in touch.

Consilient Health’s portfolio expands beyond the UK to Europe and the Middle East, for more information on this please visit www.consilienthealth.com.

Visit consilienthealth.com for more information

consilienthealth.com

Products

Women's Health

Women’s Health

Cerelle® Tablets

SPC & PIL75mcg, Blister 84

Cilique® Tablets

SPC & PIL250/35mcg, Blister 63

Gedarel Tablets

SPC & PIL20/15mcg, Blister 63
SPC & PIL30/150mcg, Blister 63

Lucette® Tablets

SPC & PIL30mcg/3mg, Blister 63

Millinette® Tablets

SPC & PIL20/75mcg, Blister 63
SPC & PIL30/75mcg, Blister 63

Rigevidon® Tablets

SPC & PILBlister 63

TriRegol® Tablets

SPC & PILBlister 63

Upostelle® Tablet

SPC & PIL1500mcg, Blister 1
Endocrinology Portfolio

Endocrinology

Bentexo Tablets

SPC & PIL70mg/5600IU, Tablets 4

Calci-D® Chewable Tablets

SPC & PIL1,000mg/1,000 IU, Tube of 28

InVita D3® Oral Drops solution

SPC & PIL2,400 IU, 1x10ml Bottle

InVita D3® Oral Solution

SPC & PIL25,000 IU, 3x1ml Ampoule
SPC & PIL50,000 IU, 3x1ml Ampoule

InVita D3® Soft Capsules

SPC & PIL400 IU, Blister 28
SPC & PIL800 IU, Blister 28
SPC & PIL5,600 IU, Blister 4
SPC & PIL25,000 IU, Blister 3
SPC & PIL50,000 IU, Blister 3
Urology

Urology

elmiron® Hard Capsule

SPC & PIL100mg, Caps Bottle 90
Cardiovascular

Cardiovascular

Atorvastatin Tablets

SPC & PIL30mg, Blister 28
SPC & PIL60mg, Blister 28

Perindopril / Amlodipine Tablets

SPC & PIL4mg/5mg, Blister 30
SPC & PIL4mg/10mg, Blister 30
SPC & PIL8mg/5mg, Blister 30
SPC & PIL8mg/10mg, Blister 30

Share this page


Code No: UK/CH/0519/0071d
Date of Preparation: April 2019